Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. This trade represents a 11.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Eric Venker also recently made the following trade(s):

• On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $29.59, for a total value of $5,918,000.00.
• On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $28.24, for a total value of $5,648,000.00.

Roivant Sciences Trading Down 3.0%

Roivant Sciences stock opened at $29.96 on Friday. The stock has a market cap of $21.44 billion, a PE ratio of -49.93 and a beta of 1.14. The stock has a 50-day moving average price of $28.46 and a 200 day moving average price of $25.06. Roivant Sciences Ltd. has a 52 week low of $10.59 and a 52 week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The firm had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter last year, the business posted ($0.29) EPS. On average, equities analysts predict that Roivant Sciences Ltd. will post -1.06 EPS for the current year.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its holdings in shares of Roivant Sciences by 8.0% during the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after purchasing an additional 235,493 shares during the period. Edgestream Partners L.P. purchased a new stake in shares of Roivant Sciences during the 1st quarter worth about $1,130,000. Janus Henderson Group PLC grew its holdings in shares of Roivant Sciences by 6.1% during the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock worth $85,790,000 after purchasing an additional 177,339 shares during the period. Arkadios Wealth Advisors purchased a new stake in shares of Roivant Sciences during the 1st quarter worth about $242,000. Finally, Amundi grew its holdings in shares of Roivant Sciences by 41.9% during the 1st quarter. Amundi now owns 1,480,970 shares of the company’s stock worth $41,023,000 after purchasing an additional 437,506 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on ROIV shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Roivant Sciences in a research report on Friday, May 8th. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research report on Thursday. Citigroup lifted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday. Finally, Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.05.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.